Poor
Not Aligned
Patient Risk:
Low
Summary
The provided claims are manufacturer/market/authorization-holder and do not appear in the supplied FDA label excerpts; no label support is available to verify them.
Category Scores
Accurate Statements
Unsupported Statements
Icatibant is manufactured by Takeda.
The supplied SAJAZIR (icatibant) label excerpts do not mention manufacturer identity (e.g., Takeda).
Icatibant is marketed under the brand Firazyr.
The supplied SAJAZIR (icatibant) label excerpts provided do not mention the brand name Firazyr.
In most markets, icatibant is sold as Firazyr.
The supplied SAJAZIR (icatibant) label excerpts do not discuss market-specific branding or prevalence by country/region.
The responsible local marketing authorization holder can differ even when the active ingredient is the same.
The supplied SAJAZIR label excerpts do not discuss regulatory/marketing authorization holder differences across markets.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
These claims relate to manufacturing/marketing/regulatory-holder information and are not tied to dosing, contraindications, warnings, interactions, or patient-use safety details in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
All statements are unsupported by the provided SAJAZIR prescribing information excerpts because they concern manufacturer/brand/authorization-holder topics not covered in those excerpts.
Suggested Improvement
Limit claims to labeling-supported content (e.g., indication, dosing/administration, warnings/precautions, adverse reactions, interactions, and population statements) or provide label sections that explicitly address manufacturer, brand naming across markets, or marketing authorization holders.